RPRX:NSC-Repros Therapeutics Inc. (USD)

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing

USD 31.95

Change

0.00 (0.00)%

Market Cap

USD 0.05B

Volume

5.90M

Analyst Target

USD 52.29
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Repros Therapeutics Inc is a development stage biopharmaceutical company. The Company is engaged in the development of new drugs to treat hormonal and reproductive system disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 126.52B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 69.68B
ARGX argenx NV ADR

N/A

USD 35.43B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 30.51B
ONC BeiGene, Ltd.

N/A

USD 26.35B
SMMT Summit Therapeutics PLC

N/A

USD 14.57B
INSM Insmed Inc

N/A

USD 12.52B
INCY Incyte Corporation

N/A

USD 11.72B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 11.50B
MRNA Moderna Inc

N/A

USD 9.91B

ETFs Containing RPRX

ROYL:AU BetaShares Global Royalti.. 6.45 % 0.00 %

N/A

N/A
KNGU:CA Brompton U.S. Cash Flow K.. 5.11 % 0.00 %

N/A

CAD 0.01B
ROYA 4.80 % 0.00 %

N/A

N/A
FORH Formidable ETF 4.63 % 0.00 %

N/A

USD 0.02B
FOVL iShares Focused Value Fac.. 3.01 % 0.25 %

N/A

USD 0.02B
FHH-F:CA First Trust AlphaDEX U.S... 2.88 % 0.00 %

N/A

CAD 0.01B
ZHU:CA BMO Equal Weight US Healt.. 1.89 % 0.00 %

N/A

CAD 0.01B
PAPI Morgan Stanley ETF Trust 0.65 % 0.00 %

N/A

USD 0.16B
IUSZ:SW iShares Edge MSCI USA Siz.. 0.41 % 0.00 %

N/A

N/A
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD 0.06B
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

N/A

CAD 0.01B
FNDA Schwab Fundamental U.S. S.. 0.00 % 0.25 %

N/A

USD 8.36B
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

N/A

N/A
IUSF:LSE iShares IV Public Limited.. 0.00 % 0.00 %

N/A

USD 0.31B
IUSZ:LSE iShares Edge MSCI USA Siz.. 0.00 % 0.00 %

N/A

USD 0.31B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

USD 0.02B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.25% 93% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.25% 93% A 94% A
Trailing 12 Months  
Capital Gain 13.22% 86% B+ 79% B-
Dividend Return 2.23% 60% D- 45% F
Total Return 15.45% 86% B+ 80% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -9.09% 40% F 23% F
Dividend Return -7.38% 42% F 25% F
Total Return 1.72% 29% F 42% F
Risk Return Profile  
Volatility (Standard Deviation) 13.43% 99% N/A 84% B
Risk Adjusted Return -54.92% 21% F 12% F
Market Capitalization 0.05B 99% N/A 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.55 33% 50%
Price/Book Ratio 2.10 48% 44%
Price / Cash Flow Ratio 6.98 4% 35%
Price/Free Cash Flow Ratio 13.14 6% 27%
Management Effectiveness  
Return on Equity 13.03% 96% 83%
Return on Invested Capital 5.36% 86% 67%
Return on Assets 4.67% 95% 83%
Debt to Equity Ratio 63.96% 31% 34%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector